公众对生殖系基因组编辑治疗特征的接受度调查
2018年荷兰成人普通公众调查(n=1857,应答率61%)采用情景问卷评估生殖系基因组编辑(GGE)治疗特征对允许临床使用支持度的影响。结果显示,GGE导致先天异常的风险影响最大(系数=-3.07),其次为有效性(系数=2.03);若有替代方案,公众强烈反对用于增强(系数=-3.37)。
要点
- GGE风险对公众支持度影响最大,公众对风险比对收益更敏感。
- 若有替代方案,公众对GGE用于增强的反对最强烈。
- 公众对GGE总体接受度高于个人使用意愿(P<0.001)。
核心结论
- GGE导致先天异常的风险对公众支持允许GGE的影响最大,其次为有效性。
- 若有替代方案,公众不是绝对反对GGE,但强烈反对用于增强。
研究设计与样本
- 2018年在荷兰普通公众中发放情景问卷调查,样本来自在线研究面板。
- 共1857名荷兰成年公众受邀,1136人应答(应答率61%),最终分析1136名应答者。
- 使用多项logit模型评估各治疗特征对受访者选择的影响。
主要发现
- 无替代方案时,GGE导致先天异常风险对支持度影响最大(系数=-3.07),其次为有效性(系数=2.03)。
- 无替代方案时,费用由国家保险覆盖(系数=-1.14)、应用类型为疾病或增强(系数=-1.07)、对儿童福祉的影响(系数=0.97)影响相似。
- 有替代方案(如PGT)时,受访者不绝对反对GGE,但强烈反对用于增强(系数=-3.37)。
- 公众对GGE的总体接受度高于个人使用意愿(P<0.001)。
- 考虑个人使用意愿时,应用类型更重要,而有效性和费用较考虑是否允许时重要性降低。
关键数值与推荐
- GGE导致先天异常风险系数=-3.07(无替代方案时对是否允许GGE的影响)。
- GGE有效性系数=2.03(无替代方案时对是否允许GGE的影响)。
- 有替代方案时GGE用于增强的系数=-3.37。
- 费用由国家保险覆盖系数=-1.14;应用类型系数=-1.07;对儿童福祉影响系数=0.97。
- 总体接受度与个人使用意愿比较P<0.001。
临床怎么用
- 公众意见可输入未来GGE伦理与治理讨论。
- 结果提示若GGE足够安全有效,公众可能支持用GGE(可能联合PGT)替代单独PGT预防疾病传递。
局限性
- 部分少数群体(如族裔、宗教)代表性不足。
- 未纳入所有GGE特征(如自付费用),情景仅反映所呈现的选择。
- 未纳入的特征可能改变所研究特征的重要性,影响系数反映现实重要性的程度。
- 仅为一个国家的单一研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: To what extent do characteristics of germline genome editing (GGE) determine whether the general public supports permitting the clinical use of GGE? SUMMARY ANSWER: The risk that GGE would cause congenital abnormalities had the largest effect on support for allowing GGE, followed by effectiveness of GGE, while costs, the type of application (disease or enhancement) and the effect on child well-being had moderate effects. WHAT IS KNOWN ALREADY: Scientific progress on GGE has increased the urgency of resolving whether and when clinical application of GGE may be ethically acceptable. Various expert bodies have suggested that the treatment characteristics will be key in determining whether GGE is acceptable. For example, GGE with substantial risks (e.g. 15% chance of a major congenital abnormality) may be acceptable to prevent a severe disease but not to enhance non-medical characteristics or traits of an otherwise healthy embryo (e.g. eye colour or perhaps in the future more complex traits, such as intelligence). While experts have called for public engagement, it is unclear whether and how much the public acceptability of GGE is affected by the treatment characteristics proposed by experts. STUDY DESIGN, SIZE, DURATION: The vignette-based survey was disseminated in 2018 among 1857 members of the Dutch general public. An online research panel was used to recruit a sample representing the adult Dutch general public. PARTICIPANTS/MATERIALS, SETTING, METHODS: A literature review identified the key treatment characteristics of GGE: the effect on the well-being of the future child, use for disease or enhancement, risks for the future child, effectiveness (here defined as the chance of a live birth, assuming that if the GGE was not successful, the embryo would not be transferred), cost and availability of alternative treatments/procedures to prevent the genetic disease or provide enhancement (i.e. preimplantation genetic testing (PGT)), respectively. For each treatment characteristic, 2-3 levels were defined to realistically represent GGE and its current alternatives, donor gametes and ICSI with PGT. Twelve vignettes were created by fractional factorial design. A multinominal logit model assessed how much each treatment characteristic affected participants' choices. MAIN RESULTS AND THE ROLE OF CHANCE: The 1136 respondents (response rate 61%) were representative of the Dutch adult population in several demographics. Respondents were between 18 and 89 years of age. When no alternative treatment/procedure is available, the risk that GGE would cause (other) congenital abnormalities had the largest effect on whether the Dutch public supported allowing GGE (coefficient = -3.07), followed by effectiveness (coefficient = 2.03). Costs (covered by national insurance, coefficient = -1.14), the type of application (disease or enhancement; coefficient = -1.07), and the effect on child well-being (coefficient = 0.97) had similar effects on whether GGE should be allowed. If an alternative treatment/procedure (e.g. PGT) was available, participants were not categorically opposed to GGE, however, they were strongly opposed to using GGE for enhancement (coefficient = -3.37). The general acceptability of GGE was higher than participants' willingness to personally use it (P < 0.001). When participants considered whether they would personally use GGE, the type of application (disease or enhancement) was more important, whereas effectiveness and costs (covered by national insurance) were less important than when they considered whether GGE should be allowed. Participants who were male, younger and had lower incomes were more likely to allow GGE when no alternative treatment/procedure is available. LIMITATIONS, REASONS FOR CAUTION: Some (e.g. ethnic, religious) minorities were not well represented. To limit complexity, not all characteristics of GGE could be included (e.g. out-of-pocket costs), therefore, the views gathered from the vignettes reflect only the choices presented to the respondents. The non-included characteristics could be connected to and alter the importance of the studied characteristics. This would affect how closely the reported coefficients reflect 'real-life' importance. WIDER IMPLICATIONS OF THE FINDINGS: This study is the first to quantify the substantial impact of GGE's effectiveness, costs (covered by national insurance), and effect on child well-being on whether the public considered GGE acceptable. In general, the participants were strikingly risk-averse, in that they weighed the risks of GGE more heavily than its benefits. Furthermore, although only a single study in one country, the results suggests that-if sufficiently safe and effective-the public may approve of using GGE (presumably combined with PGT) instead of solely PGT to prevent passing on a disease. The reported public views can serve as input for future consideration of the ethics and governance of GGE. STUDY FUNDING/COMPETING INTEREST(S): Young Academy of the Royal Dutch Academy of Sciences (UPS/RB/745), Alliance Grant of the Amsterdam Reproduction and Development Research Institute (2017-170116) and National Institutes of Health Intramural Research Programme. No competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- van Dijke I, van Wely M, Berkman BE, et al. Should germline genome editing be allowed? The effect of treatment characteristics on public acceptability. Hum Reprod. 2021. PMID: 33242333. doi:10.1093/humrep/deaa212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。